Epigenomic?s AG Announces 2013 Third Quarter and 9-Month Financial Results and Reports on Operationa?l Highlights
Epigenomics AG, the German–American cancer molecular diagnostics company, has announced its financial results for the third quarter and the 9 months ending 30 September 2013.
• 9M 2013 revenue increased by 43% to EUR 961 thousand
• 9M 2013 operating costs decreased by 40% to EUR 6.6 million
• 9M 2013 EBIT improved by 45% to EUR -5.2 million
• Strategic partnerships with Polymedco for the US and BioChain for China (after period-end)
• Successful financing of EUR 5.2 million closed (thereof EUR 4.7 million after period-end)
• Supervisory Board re-appoints Thomas Taapken as CEO/CFO until end of 2015.
“In the past weeks we have achieved significant progress as evidenced by two strategically important collaborations we entered into with Polymedco and BioChain and by securing a EUR 5.2 million financing for the future development of our company. We are especially proud that both of our new partners, BioChain and Polymedco, have expressed their commitment and trust in Epigenomics by becoming strategic investors,, said Thomas Taapken, CEO/CFO of Epigenomics AG.
“Investor confidence in Epigenomics finally seems to be returning; our share price has tripled since the beginning of this year. We are committed to live up to these high expectations to the benefit of our shareholders and partners and remain confident to receive FDA approval for Epi proColon in the near future.”
Click here for the full 2013 Third Quarter and 9-Month Financial Report
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance